Behavioral effects of the imidazoline I2 receptor ligand BU99006 in rats

Behavioural Pharmacology

Volumn 25, Issue 2, 2014, Pages 130-136

  Qiu, Yanyan ^a,b   Thorn, David A ^b   Zhang, Yanan ^c   He, Xiaohua ^a   Li, Jun Xu ^b  

^a WUHAN UNIVERSITY   (China)

^b UNIVERSITY AT BUFFALO   (United States)

^c RTI INTERNATIONAL   (United States)

Author keywords

2 BFI; BU99006; drug discrimination; hypothermia; rat

Indexed keywords

BU 99006; IMIDAZOLE DERIVATIVE; IMIDAZOLINE I2 RECEPTOR; UNCLASSIFIED DRUG; 2-(2-BENZOFURANYL)-2-IMIDAZOLINE; BENZOFURAN DERIVATIVE; CENTRAL NERVOUS SYSTEM AGENTS; IDAZOXAN; IMIDAZOLINE RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY TEMPERATURE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DRUG DISCRIMINATION; HYPOTHERMIA; MALE; NONHUMAN; RAT; AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; DOSE RESPONSE; DRUG EFFECTS; PERCEPTIVE DISCRIMINATION; SPRAGUE DAWLEY RAT;

ANIMALS; BENZOFURANS; BODY TEMPERATURE; CENTRAL NERVOUS SYSTEM AGENTS; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; HYPOTHERMIA; IDAZOXAN; IMIDAZOLES; IMIDAZOLINE RECEPTORS; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84896403508     PISSN: 09558810     EISSN: 14735849     Source Type: Journal    
DOI: 10.1097/FBP.0000000000000028     Document Type: Article

References (32)

1. 2 receptor-mediated mechanism. Pharmacol Biochem Behav 103:550-560.
2. Bousquet P, Feldman J, Schwartz J (1984). Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazo-lines. J Pharmacol Exp Ther 230:232-236.
3. Eglen RM, Hudson AL, Kendall DA, Nutt DJ, Morgan NG, Wilson VG, et al. (1998). 'Seeing through a glass darkly': casting light on imidazoline 'I' sites. Trends Pharmacol Sci 19:381-390.
4. Ferrari F, Fiorentino S, Mennuni L, Garofalo P, Letari O, Mandelli S, et al. (2011). Analgesic efficacy of CR4056, a novel imidazoline-2 receptor ligand, in rat models of inflammatory and neuropathic pain. J Pain Res 4:111-125.
5. 2 receptor selective ligand BU224 in naive rats and rats exposed to the stress of the forced swim test. Psychopharmacology (Berl) 167:195-202.
6. 2-imidazoline receptor ligands decreases the content of pro-apoptotic markers in rat brain. J Psychopharmacol 27:123-134.
7. Garcia-Sevilla JA, Ferrer-Alcon M (2003). In vivo effects of the I(2)-alkylating agent BU99006 on the immunodensity of imidazoline receptor proteins in the mouse brain. Ann N Y Acad Sci 1009:323-331.
8. Head GA, Mayorov DN (2006). Imidazoline receptors, novel agents and therapeutic potential. Cardiovasc Hematol Agents Med Chem 4:17-32.
9. Hudson AL, Tyacke RJ, Lalies MD, Davies N, Finn DP, Marti O, et al. (2003). Novel ligands for the investigation of imidazoline receptors and their binding proteins. Ann N Y Acad Sci 1009:302-308.
10. 2 site ligand, 2-BFI. J Psychopharmacol 10:273-278.
11. Kimura A, Tyacke RJ, Robinson JJ, Husbands SM, Minchin MC, Nutt DJ, et al. (2009). Identification of an imidazoline binding protein: creatine kinase and an imidazoline-2 binding site. Brain Res 1279:21-28.
12. Li JX, Koek W, France CP (2009). Food restriction and streptozotocin differentially modify sensitivity to the hypothermic effects of direct-and indirect-acting serotonin receptor agonists in rats. Eur J Pharmacol 613:60-63.
13. 2 receptors: target for new analgesics? Eur J Pharmacol 658:49-56.
14. 2 receptor ligands. Eur J Pharmacol 669:59-65.
15. Li JX, Thorn DA, Jin C (2013). The GPR88 receptor agonist 2-PCCA does not alter the behavioral effects of methamphetamine in rats. Eur J Pharmacol 698:272-277.
16. MacInnes N, Handley SL (2002). Characterization of the discriminable stimulus produced by 2-BFI: effects of imidazoline I(2)-site ligands, MAOIs, beta-carbolines, agmatine and ibogaine. Br J Pharmacol 135:1227-1234.
17. 2-site ligand 2-BFI. Pharmacol Biochem Behav 75:427-433.
18. 2-site-specific ligands and monoamine oxidase inhibitors in rats with a unilateral 6-hydroxydopamine lesion of the nigrostriatal pathway. Br J Pharmacol 143:952-959.
19. 2 ligand, is highly effective against bortezomib-induced painful neuropathy in rats. J Pain Res 5:151-167.
20. Morgan NG, Chan SL (2001). Imidazoline binding sites in the endocrine pancreas: can they fulfill their potential as targets for the development of new insulin secretagogues? Curr Pharm Des 7:1413-1431.
21. Nikolic K, Agbaba D (2012). Pharmacophore development and SAR studies of imidazoline receptor ligands. Mini Rev Med Chem 12:1542-1555.
22. 2 binding sites. Neuropharmacology 52:395-404.
23. Regunathan S, Reis DJ (1996). Imidazoline receptors and their endogenous ligands. Annu Rev Pharmacol Toxicol 36:511-544.
24. 2 receptor ligands on acute nociception in rats. Neuroreport 23:73-77.
25. Sánchez-Blázquez P, Boronat MA, Olmos G, Garćia-Sevilla JA, Garzón J (2000). Activation of I(2)-imidazoline receptors enhances supraspinal morphine analgesia in mice: a model to detect agonist and antagonist activities at these receptors. Br J Pharmacol 130:146-152.
26. Sastre-Coll A, Esteban S, Miralles A, Zanetti R, Garćia-Sevilla JA (2001). The imidazoline receptor ligand 2-(2-benzofuranyl)-2-imidazoline is a dopamine-releasing agent in the rat striatum in vivo. Neurosci Lett 301:29-32.
27. Sun Z, Chang CH, Ernsberger P (2007). Identification of IRAS/nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells. J Neurochem 101:99-108.
28. 2 receptor agonists in rats. Br J Pharmacol 166:1936-1945.
29. 2 ligand 2-BFI in mice. Prog Neuropsychopharmacol Biol Psychiatry 37:15-21.
30. Tyacke RJ, Robinson ES, Nutt DJ, Hudson AL (2002). 5-Isothiocyanato-2- benzofuranyl-2-imidazoline (BU99006) an irreversible imidazoline(2) binding site ligand: in vitro and in vivo characterisation in rat brain. Neuropharmacol-ogy 43:75-83.
31. Walker EA, Zernig G, Woods JH (1995). Buprenorphine antagonism of the mu opioids in the rhesus monkey tail-withdrawal procedure. J Pharmacol Exp Ther 273:1345-1352.
32. Ward SJ, Portoghese PS, Takemori AE (1982). Pharmacological characterization in vivo of the novel opiate, b-funaltrexamine. J Pharmacol Exp Ther 220:494-498.